Adaptive Biotechnologies

Historical price data

Adaptive Biotechnologies is translating the genetics of the adaptive immune system into clinical insights and novel therapies. Founded in 2009, the company has commercialized the clonoSEQ MRD assay and built a massive database of immune receptor sequences to fuel its drug discovery engine. Its strategic direction focuses on expanding its diagnostic portfolio and advancing its pipeline of TCR and antibody therapeutics through internal development and partnerships.

The Immune Medicine Platform uses proprietary chemistry, computational biology, and machine learning to sequence, map, pair, and characterize T-cell and B-cell receptors at scale, translating immune system genetics into a clinical database for diagnostics and drug discovery.

4 drugs in pipeline

Total raised: $620M

Adaptive competes in MRD testing with Natera and Guardant Health, differentiated by clonoSEQ's FDA clearance. In immune drug discovery, it competes with platform companies like Immunai and TCR-focused firms like Immunocore, differentiated by its scale of paired receptor data and integrated diagnostic-therapeutic strategy.